Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon

Revista da Sociedade Brasileira de Medicina Tropical

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil¹  Moura-Neto, José Pereira¹  Monteiro, Wuelton Marcelo¹  Almeida, Anne Cristine Gomes de¹  Universidade de Brasília, Brasília, Brazil¹  Oliveira, Maria Regina Fernandes de¹  Universidade Federal do Amazonas, Manaus, Brazil¹  Universidade do Estado do Amazonas, Manaus, Brazil¹  Lacerda, Marcus Vinícius Guimarães de¹  Instituto Nacional de Avaliação de Tecnologias em Saúde, Porto Alegre, Brazil¹  Case Western Reserve University, Cleveland, USA¹  Brito, Marcelo Augusto Mota¹  Peixoto, Henry Maia¹  Romero, Gustavo Adolfo Sierra¹  Fundação Oswaldo Cruz, Manaus, Brazil¹  Singh, Nakul¹ 

关键词:  Malaria;    Plasmodium vivax;    Glucose-6-phosphate dehydrogenase deficiency;    Care Start G6PD;   

DOI  :  10.1590/0037-8682-0134-2016

学科分类：农业科学（综合）

来源: Sociedade Brasileira de Medicina Tropical

【 摘 要 】

INTRODUCTION: In the Brazilian Amazon, malaria infections are primarily caused by Plasmodium vivax. The only drug that kills the hypnozoite form of P. vivax is primaquine, thereby preventing relapse. However, treating glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals with primaquine can lead to severe hemolysis. G6PD deficiency (G6PDd) affects approximately 400 million people worldwide, most of whom live in malaria-endemic areas. Therefore, clinicians need tools that can easily and reliably identify individuals with G6PDd. This study estimated the accuracy of the Carestart(tm) G6PD rapid test (Access Bio) in the diagnosis of G6PDd in male participants with and without P. vivax acute malaria.

【 授权许可】

Unknown